Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMirallas Viñas, Oriol
dc.contributor.authorLópez-Valbuena, D.
dc.contributor.authorGarcía Illescas, David
dc.contributor.authorFabregat Franco, Carles
dc.contributor.authorVerdaguer Mata, Helena
dc.contributor.authorTabernero Caturla, Josep
dc.contributor.authorMacarulla Mercadé, Teresa
dc.date.accessioned2022-09-09T13:30:21Z
dc.date.available2022-09-09T13:30:21Z
dc.date.issued2022-06
dc.identifier.citationMirallas O, López-Valbuena D, García-Illescas D, Fabregat-Franco C, Verdaguer H, Tabernero J, et al. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer. ESMO Open. 2022 Jun;7(3):100503.
dc.identifier.issn2059-7029
dc.identifier.urihttp://hdl.handle.net/11351/8125
dc.descriptionBiliary tract cancer; Molecular testing; Next-generation sequencing
dc.description.abstractIntroduction Biliary tract cancers (BTCs) are a rare and heterogenous group with an increasing incidence and high mortality rate. The estimated new cases and deaths of BTC worldwide are increasing, but the incidence and mortality rates in South East Asia are the highest worldwide, representing a real public health problem in these regions. BTC has a poor prognosis with a median overall survival <12 months. Thus, an urgent unmet clinical need for BTC patients exists and must be addressed. Results The backbone treatment of these malignancies is chemotherapy in first- and second-line setting, but in the last decade a rich molecular landscape has been discovered, expanding conceivable treatment options. Some druggable molecular aberrations can be treated with new targeted therapies and have already demonstrated efficacy in patients with BTC, improving clinical outcomes, such as the FGFR2 or IDH1 inhibitors. Many other molecular alterations are being discovered and the treatment of BTC will change in the near future from our current clinical practice. Conclusions In this review we discuss the epidemiology, molecular characteristics, present treatment approaches, review the recent therapeutic advances, and explore future directions for patients with BTC. Due to the rich molecular landscape of BTC, molecular profiling should be carried out early. Ongoing research will bring new targeted treatments and immunotherapy in the near future.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesESMO Open;7(3)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectTracte biliar - Càncer - Tractament
dc.subjectFarmacologia molecular
dc.subjectImmunoteràpia
dc.subject.meshBiliary Tract Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshMolecular Targeted Therapy
dc.subject.meshImmunotherapy
dc.titleAdvances in the systemic treatment of therapeutic approaches in biliary tract cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.esmoop.2022.100503
dc.subject.decsneoplasias del tracto biliar
dc.subject.decs/farmacoterapia
dc.subject.decsterapia molecular selectiva
dc.subject.decsinmunoterapia
dc.relation.publishversionhttps://doi.org/10.1016/j.esmoop.2022.100503
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliationServei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid35696747
dc.identifier.wos000836447800003
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record